Rajeev Juneja contributes ₹9.17 crore to National Defence Fund, marks continued support for Armed Forces

Rajeev Juneja, Vice Chairman and Managing Director of Mankind Pharma, has contributed ₹9,17,91,950 to the National Defence Fund, marking the first anniversary of Operation Sindoor and reaffirming his continued support for the Armed Forces.

The number 9 is a reference to the nine terror bases targeted during the operation, while the remaining digits are a reference to the birth date of Prime Minister Narendra Modi, making the contribution a deliberate and meaningful figure rather than a rounded sum.

This marks the second consecutive year that Mr Juneja has made a personal contribution towards supporting the Armed Forces. The decision, he noted, is rooted in the belief that such support should be consistent and not limited to moments of heightened public attention.

“In moments of crisis, we come together with a strong sense of intent. But as time passes, that intensity often fades. For the Armed Forces, however, the responsibility never changes. Their commitment is constant, regardless of public attention. This contribution is a small way of recognising that continuity. It is not meant to be a one-time gesture, but part of an ongoing effort to support those who serve the nation every day. I also believe that when it comes to the nation, sharing such actions can encourage wider participation. Collective effort creates far greater impact than individual intent.”

He added that his perspective is also shaped by personal history. His family was displaced during Partition, with roots in Bahawalpur, and the experience of loss and rebuilding has remained deeply ingrained in his worldview. This lived history continues to inform his emotional connection to the nation and its security forces, particularly in moments when the country confronts threats originating from the same region.

The contribution builds on a broader record of support during national crises. During the COVID-19 pandemic, Mankind Pharma extended financial and on-ground assistance to frontline workers and affected families, including long-term support initiatives.

About Mankind Pharma 

Mankind Pharma (BSE: 543904 | NSE: MANKIND) is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence. Mankind operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company is a leading player in the domestic pharmaceuticals business present across acute and chronic therapeutic areas including anti-infectives, cardiovascular, Gr Mankind/II- gastrointestinal, antidiabetic, neuro/CNS, gynecology, VMN and respiratory, among others with a strategy to increase chronic presence going ahead. In the consumer healthcare business, the company operates in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories, among others, with several category-leading brands. Following the acquisition of Bharat Serums and Vaccines Limited, Mankind Pharma has further strengthened its leadership in the domestic women’s health segment. Mankind’s distribution network includes a robust field force of 17,700+ professionals, and a reach extending to over five lakh doctors across urban and rural markets. The company has 32 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. Mankind has a consistent track record of product innovation through 6 dedicated R&D facilities backed by more than 730 scientists

For more information, visit www.mankindpharma.com or contact: 

Natasha Raj – 9205057627 – natasha.raj@mankindpharma.com 

Apoorva Sharma – 9999739452 – apoorva.sharma@adfactorspr.com